{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:53:39Z","timestamp":1793235219967,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.8873","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:52:52Z","timestamp":1651276372000},"page":"e228873","source":"Crossref","is-referenced-by-count":190,"title":["Association of Influenza Vaccination With Cardiovascular Risk"],"prefix":"10.1001","volume":"5","author":[{"given":"Bahar","family":"Behrouzi","sequence":"first","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation and Temerty Faculty of Medicine, University of Toronto, Toronto, Canada"},{"name":"ICES, Toronto, Canada"},{"name":"Cardiovascular Division, Department of Medicine, Women\u2019s College Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation and Temerty Faculty of Medicine, University of Toronto, Toronto, Canada"},{"name":"ICES, Toronto, Canada"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management, and Evaluation and Temerty Faculty of Medicine, University of Toronto, Toronto, Canada"},{"name":"ICES, Toronto, Canada"},{"name":"Cardiovascular Division, Department of Medicine, Women\u2019s College Hospital, Toronto, Canada"},{"name":"Peter Munk Cardiac Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"15","key":"zoi220269r1","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2020.08.028","article-title":"Influenza vaccination to reduce cardiovascular morbidity and mortality in patients with COVID-19: JACC state-of-the-art review.","volume":"76","author":"Behrouzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi220269r2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1473-3099(09)70331-7","article-title":"Role of acute infection in triggering acute coronary syndromes.","volume":"10","author":"Corrales-Medina","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"zoi220269r3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/M20-1509","article-title":"Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study.","volume":"173","author":"Chow","year":"2020","journal-title":"Ann Intern Med"},{"issue":"16","key":"zoi220269r4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.2013.279206","article-title":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.","volume":"310","author":"Udell","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"zoi220269r5","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial.","volume":"144","author":"Fr\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"zoi220269r7","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"zoi220269r8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ehj.2003.10.018","article-title":"Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study.","volume":"25","author":"Gurfinkel","year":"2004","journal-title":"Eur Heart J"},{"issue":"11","key":"zoi220269r9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/eurheartj\/ehm581","article-title":"Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study.","volume":"29","author":"Ciszewski","year":"2008","journal-title":"Eur Heart J"},{"issue":"14","key":"zoi220269r10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1093\/eurheartj\/ehr004","article-title":"Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome.","volume":"32","author":"Phrommintikul","year":"2011","journal-title":"Eur Heart J"},{"issue":"21","key":"zoi220269r11","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.1994.03520210045030","article-title":"The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial.","volume":"272","author":"Govaert","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"zoi220269r12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.vaccine.2009.09.092","article-title":"Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older.","volume":"28","author":"De Villiers","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"zoi220269r13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.23649","article-title":"Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial.","volume":"325","author":"Vardeny","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"zoi220269r14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41569-021-00670-w","article-title":"Universal flu vaccines: a shot at lifelong cardioprotection?","volume":"19","author":"Behrouzi","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"zoi220269r15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ahj.2021.03.007","article-title":"Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial.","volume":"237","author":"Hollingsworth","year":"2021","journal-title":"Am Heart J"},{"key":"zoi220269r16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ahj.2019.02.009","article-title":"Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design.","volume":"212","author":"Loeb","year":"2019","journal-title":"Am Heart J"},{"issue":"2","key":"zoi220269r18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"10","key":"zoi220269r21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jchf.2018.04.012","article-title":"Vaccination trends in patients with heart failure: insights from get with the guidelines-heart failure.","volume":"6","author":"Bhatt","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"2","key":"zoi220269r22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jchf.2018.10.011","article-title":"Effect of influenza on outcomes in patients with heart failure.","volume":"7","author":"Panhwar","year":"2019","journal-title":"JACC Heart Fail"},{"key":"zoi220269r23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.amjcard.2020.05.045","article-title":"Influence of influenza infection on in-hospital acute myocardial infarction outcomes.","volume":"130","author":"Tripathi","year":"2020","journal-title":"Am J Cardiol"},{"key":"zoi220269r6","unstructured":"World Health Organization Global Influenza Surveillance and Response System (GISRS). Influenza Laboratory Surveillance Information. Published 2022. Accessed September 30, 2021. https:\/\/apps.who.int\/flumart\/Default?ReportNo=7"},{"key":"zoi220269r17","doi-asserted-by":"crossref","unstructured":"Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting (DANFLU-1). ClinicalTrials.gov identifier: NCT05048589. Updated October 8, 2021. Accessed October 11, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05048589","DOI":"10.1186\/s40814-022-01044-w"},{"key":"zoi220269r19","doi-asserted-by":"crossref","unstructured":"Massare? MJ, Patel? N, Zhou? B, Maciejewski? S, Flores? R, Guebre-Xab? M. Combination respiratory vaccine containing recombinant Sars-CoV-2 spike and quadrivalent seasonal influenza hemagglutinin nanoparticles with matrix-m adjuvant.? bioRxiv. Preprint posted May 5, 2021. doi:10.1101\/2021.05.05.442782","DOI":"10.1101\/2021.05.05.442782"},{"key":"zoi220269r20","unstructured":"Moderna announces significant advances across industry-leading mRNA portfolio at 2021 R&D Day. Moderna press release. Published September 9, 2021. Accessed February 7, 2022. https:\/\/investors.modernatx.com\/news\/news-details\/2021\/Moderna-Announces-Significant-Advances-Across-Industry-Leading-mRNA-Portfolio-at-2021-RD-Day-09-09-2021\/default.aspx"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2791733\/behrouzi_2022_oi_220269_1650561528.08384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T23:52:58Z","timestamp":1651276378000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791733"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8873","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}